Abstract

Background: The aim of our research was to evaluate the oxidative and inflammatory biomarkers of oxidative stress (OS) in blood samples of patients with Psoriatic Arthritis compared to healthy controls.
Materials and Methods: Our study involved 40 patients with Psoriatic Arthritis and 40 generally healthy subjects matched by age and gender to the study group patients. In this study we have evaluated the haematological and lipid profiles in healthy control and patients group. We have also assessed the concentration/activity of antioxidant enzymes: Superoxide Dismutase (SOD), glutathione peroxidase (GPx), Catalase (CAT) and total antioxidative status (TAS), and lipid oxidation products: Malondialdehyde (MDA) were estimated. Serum ADA, hsCRP, SUA, and ESR were evaluated for patients and controls. The extent of disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and Dermatology Quality Of Life Index (DLQI) and patients were grouped into having mild, moderate and severe disease using these scores.
Results: Comparison among healthy control and psoriasis patients; there were no statistical differences concerning age, body mass index, and fasting serum glucose level. A significant increase in malondialdehyde (MDA), Nitric Oxide end products (NOx) and hsCRP levels (p<0.001) was noted in Psoriasis patients as compared to controls. The concentration of GPx, CAT, and SOD was significantly higher in patients with Psoriatic Arthritis compared to healthy subjects.
Conclusions: Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the outcome of therapy and of the development of co-morbidities. Our findings revealed that an imbalance of oxidative stress and antioxidant factors might contribute to the pathogenesis of psoriasis. Therefore, treatment based on antioxidant strategies might be beneficial in psoriasis management.